NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Denmark's Nordic Bioscience have announced a collaboration to develop biomarkers to help diagnose and monitor scar-tissue related to diseases of the liver.

Under the terms of the agreement, the partners will develop biomarkers and diagnostics to evaluate non-alcoholic steatohepatitis (NASH) in pre-clinical models of fibrotic diseases and in clinical settings.

Nordic Bioscience brings to the collaboration experience developing assays using collagens, elastins, and laminins as biomarkers of the extracellular matrix.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.